{"id":6807,"date":"2021-05-07T17:29:01","date_gmt":"2021-05-07T17:29:01","guid":{"rendered":"https:\/\/valutico.com\/evaluations-hebdomadaires-pfizer\/"},"modified":"2024-01-05T20:34:49","modified_gmt":"2024-01-05T20:34:49","slug":"weekly-valuations-pfizer","status":"publish","type":"post","link":"https:\/\/valutico.com\/weekly-valuations-pfizer\/","title":{"rendered":"Weekly Valuations: Pfizer"},"content":{"rendered":"
Pharmaceutical giant Pfizer beat earnings expectations this week, the company lifted its guidance and also announced plans to donate Covid-19 vaccines to Olympic athletes for the upcoming summer games.<\/span><\/p>\n Turned into a mainstream discussion topic by the pandemic, the pharmaceutical giant capitalized on its success in creating a vaccine to reap huge rewards, for the year 2021, Pfizer estimates it could generate as much as $26 billion in revenue, an increase from earlier estimates of \u201cjust\u201d $15 billion.<\/span><\/p>\n That said, many analysts remain cautious about the company\u2019s outlook beyond the pandemic, as concerns over its long term pipeline remain.<\/span><\/p>\n But what is Pfizer really worth:<\/span><\/p>\n With a market cap of $223Bn the company is the 3rd largest in its market, behind JnJ and Roche, but is it fairly valued?<\/span><\/p>\n Our income based models, both DCF and DDM seem to suggest it could be as much as $100Bn undervalued, as they both yield values north of $300Bn (assuming, per analysts consensus estimates that 2021 revenue represents nearly 70% growth over 2020, and that 2022 would see a large retraction post-vaccine).<\/span><\/p>\n But our market based methods seem more in line with the company\u2019s current market cap, closer to $250Bn<\/span><\/p>\n What is your outlook on the pharma behemoth?<\/span><\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n